17.99
price up icon0.62%   0.11
after-market After Hours: 17.94 -0.05 -0.28%
loading
Rigel Pharmaceuticals stock is traded at $17.99, with a volume of 421.52K. It is up +0.62% in the last 24 hours and down -21.99% over the past month.
See More
Previous Close:
$17.88
Open:
$17.39
24h Volume:
421.52K
Relative Volume:
1.59
Market Cap:
$366.91M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-128.50
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
-12.41%
1M Performance:
-21.99%
6M Performance:
+11.19%
1Y Performance:
+21.55%
1-Day Range:
Value
$17.01
$18.45
1-Week Range:
Value
$17.01
$20.62
52-Week Range:
Value
$7.4843
$29.82

Rigel Pharmaceuticals Stock (RIGL) Company Profile

Name
Name
Rigel Pharmaceuticals
Name
Phone
650-624-1100
Name
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Name
Employee
0
Name
Twitter
@rigelpharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
RIGL's Discussions on Twitter

Compare RIGL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RIGL
Rigel Pharmaceuticals
17.99 366.91M 116.88M -25.09M -20.74M -0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-03-23 Resumed Piper Sandler Neutral
Jun-09-22 Downgrade Citigroup Buy → Neutral
Jun-08-22 Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-08-22 Downgrade Piper Sandler Overweight → Neutral
Mar-23-22 Initiated B. Riley Securities Neutral
Nov-09-20 Downgrade JP Morgan Overweight → Neutral
Nov-15-19 Resumed Cantor Fitzgerald Overweight
Sep-26-19 Resumed JP Morgan Overweight
Mar-01-19 Reiterated Cantor Fitzgerald Overweight
Aug-27-18 Initiated Citigroup Buy
May-02-18 Reiterated Cantor Fitzgerald Overweight
Dec-21-17 Resumed Piper Jaffray Overweight
Dec-15-17 Initiated Cantor Fitzgerald Overweight
Nov-06-17 Resumed H.C. Wainwright Buy
Mar-09-17 Reiterated H.C. Wainwright Buy
Aug-31-16 Reiterated H.C. Wainwright Buy
Aug-30-16 Reiterated Piper Jaffray Overweight
Jul-13-16 Initiated H.C. Wainwright Buy
Jun-13-16 Initiated Piper Jaffray Overweight
Apr-22-16 Upgrade JP Morgan Neutral → Overweight
Apr-08-13 Reiterated Stifel Buy
Nov-29-12 Initiated UBS Neutral
Nov-06-12 Reiterated Oppenheimer Outperform
Mar-26-12 Initiated Canaccord Genuity Hold
Dec-10-10 Downgrade MP Advisors Outperform → Market Perform
View All

Rigel Pharmaceuticals Stock (RIGL) Latest News

pulisher
Mar 27, 2025

Rigel settles patent litigation regarding its immune thrombocytopenia treatment - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Pharma stock rises on patent settlement (RIGL:NASDAQ) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel, Hetero Settle Patent Suit Over Platelet-Booster Tavalisse - Bloomberg Law News

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel climbs on blood disorder drug patent settlement - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel settles patent litigation regarding its immune thrombocytopenia treatment (RIGL:NASDAQ) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Pharmaceuticals resolves patent litigation related to Tavalisse - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel settles patent litigation over TAVALISSE treatment - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Wins Patent Battle: TAVALISSE Exclusivity Protected Until 2032 in Major Settlement - Stock Titan

Mar 27, 2025
pulisher
Mar 25, 2025

(RIGL) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 25, 2025
pulisher
Mar 25, 2025

Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma

Mar 25, 2025
pulisher
Mar 21, 2025

Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors - MSN

Mar 21, 2025
pulisher
Mar 15, 2025

Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

(RIGL) Investment Analysis and Advice - news.stocktradersdaily.com

Mar 15, 2025
pulisher
Mar 13, 2025

Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 11, 2025

Rigel Looks Interesting, But Let's Wait For A Lower Price (NASDAQ:RIGL) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals adds oncology expert to board By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

SEC Form 4 filed by Director Frohlich Mark W - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals appoints new board member - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals Appoints Dr. Frohlich to Board - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel appoints Mark W. Frohlich to its board -March 10, 2025 at 12:01 pm EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals adds oncology expert to board - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Has $423,000 Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

FY2025 EPS Estimates for RIGL Increased by Cantor Fitzgerald - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Citigroup Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal - MSN

Mar 08, 2025
pulisher
Mar 08, 2025

Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to “Buy” - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

What is B. Riley’s Forecast for RIGL Q1 Earnings? - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

What is HC Wainwright’s Estimate for RIGL Q1 Earnings? - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Earnings call transcript: Rigel Pharmaceuticals Q4 2024 sees strong growth By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Reiterates Buy Rating for Rigel Pharmaceuticals (NASDAQ:RIGL) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

What is B. Riley’s Estimate for RIGL FY2026 Earnings? - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q3 Earnings Forecast for RIGL Issued By HC Wainwright - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Rigel Pharmaceuticals price target raised to $55 from $49 at Citi - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Citi lifts Rigel stock price target to $55, maintains Buy rating - Investing.com

Mar 06, 2025
pulisher
Mar 05, 2025

Rigel Pharmaceuticals Reports Record Sales and Strategic Growth - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 05, 2025
pulisher
Mar 05, 2025

Rigel Pharmaceuticals stock holds Buy rating, $57 target By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Rigel Pharmaceuticals stock holds Buy rating, $57 target - Investing.com India

Mar 05, 2025

Rigel Pharmaceuticals Stock (RIGL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):